Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.84 Million GBP | -33.29% |
| 2022 | -7.25 Million GBP | -13.47% |
| 2021 | -6.42 Million GBP | -46.53% |
| 2020 | -4.46 Million GBP | -45.48% |
| 2019 | -2.99 Million GBP | -43.36% |
| 2018 | -2.09 Million GBP | 4.17% |
| 2017 | -3.78 Million GBP | -49.42% |
| 2016 | -1.9 Million GBP | -60.2% |
| 2015 | -1.27 Million GBP | -32.56% |
| 2014 | -688 Thousand GBP | 26.73% |
| 2013 | -939 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.83 Million GBP | 0.0% |
| 2024 Q1 | -2.83 Million GBP | -12.09% |
| 2023 Q2 | -4.34 Million GBP | -95.94% |
| 2023 Q1 | -2.21 Million GBP | 45.55% |
| 2023 Q4 | -5.29 Million GBP | -109.3% |
| 2023 Q3 | -2.52 Million GBP | 41.87% |
| 2023 FY | - GBP | -33.29% |
| 2022 Q3 | -2.1 Million GBP | 42.45% |
| 2022 FY | - GBP | -13.47% |
| 2022 Q1 | -1.88 Million GBP | 40.69% |
| 2022 Q2 | -3.66 Million GBP | -93.97% |
| 2022 Q4 | -4.07 Million GBP | -93.27% |
| 2021 Q4 | -3.18 Million GBP | -78.63% |
| 2021 Q2 | -3.24 Million GBP | -96.66% |
| 2021 Q1 | -1.64 Million GBP | 30.43% |
| 2021 FY | - GBP | -46.53% |
| 2021 Q3 | -1.78 Million GBP | 44.99% |
| 2020 FY | - GBP | -45.48% |
| 2020 Q2 | -2.11 Million GBP | -94.94% |
| 2020 Q3 | -1.22 Million GBP | 42.0% |
| 2020 Q1 | -1.08 Million GBP | 42.39% |
| 2020 Q4 | -2.36 Million GBP | -92.84% |
| 2019 FY | - GBP | -43.36% |
| 2019 Q1 | -744 Thousand GBP | -30.18% |
| 2019 Q4 | -1.88 Million GBP | -104.11% |
| 2019 Q2 | -744 Thousand GBP | 0.0% |
| 2019 Q3 | -924 Thousand GBP | -24.19% |
| 2018 FY | - GBP | 4.17% |
| 2018 Q1 | -564 Thousand GBP | -5.13% |
| 2018 Q2 | -564 Thousand GBP | 0.0% |
| 2018 Q3 | -571.5 Thousand GBP | -1.33% |
| 2018 Q4 | -571.5 Thousand GBP | 0.0% |
| 2017 Q3 | -536.5 Thousand GBP | 10.43% |
| 2017 FY | - GBP | -49.42% |
| 2017 Q4 | -536.5 Thousand GBP | 0.0% |
| 2017 Q2 | -599 Thousand GBP | 0.0% |
| 2017 Q1 | -599 Thousand GBP | -72.87% |
| 2016 Q1 | -511 Thousand GBP | -9.3% |
| 2016 Q2 | -511 Thousand GBP | 0.0% |
| 2016 Q4 | -346.5 Thousand GBP | 0.0% |
| 2016 FY | - GBP | -60.2% |
| 2016 Q3 | -346.5 Thousand GBP | 32.19% |
| 2015 Q4 | -467.5 Thousand GBP | 0.0% |
| 2015 Q3 | -467.5 Thousand GBP | -61.21% |
| 2015 FY | - GBP | -32.56% |
| 2015 Q1 | -290 Thousand GBP | 0.0% |
| 2015 Q2 | -290 Thousand GBP | 0.0% |
| 2014 FY | - GBP | 26.73% |
| 2013 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -462.343% |
| Skye Bioscience, Inc. | -13.54 Million USD | 27.36% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 110.465% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1965.829% |
| Qrons Inc. | -40.08 Thousand USD | -24452.781% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2579.858% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -153.352% |
| BioStem Technologies, Inc. | -7.55 Million USD | -30.281% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -950.324% |
| CSL Limited | 4.78 Billion USD | 100.205% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 82.217% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 43.345% |
| Rebus Holdings, Inc. | -951 Thousand USD | -934.805% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1456.121% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 37.989% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 86.146% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -65.983% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -4014.991% |
| SQZ Biotechnologies Company | -64.14 Million USD | 84.657% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -272.138% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -540.67% |
| Mesoblast Limited | -62.38 Million USD | 84.227% |
| Marizyme, Inc. | -34.28 Million USD | 71.294% |
| Genus plc | 73.7 Million USD | 113.353% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -48.846% |
| Pharming Group N.V. | 9.87 Million USD | 199.636% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -561.619% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -177.446% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -12.187% |
| ContraFect Corporation | -64.99 Million USD | 84.86% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -117.423% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -602.022% |
| IMV Inc. | -35.52 Million USD | 72.297% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -323.484% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1799.638% |
| ONE Bio Corp. | 13.61 Million USD | 172.291% |
| Accustem Sciences Inc. | -3.74 Million USD | -162.678% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 79.594% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -676.636% |
| Q BioMed Inc. | -617.62 Thousand USD | -1493.354% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 375.504% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -330.775% |
| Biomind Labs Inc. | -1.03 Million USD | -851.236% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 75.172% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -240.245% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -37.42% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 146456.336% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -39264.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -293.331% |
| GB Sciences, Inc. | -1.41 Million USD | -593.084% |
| Alpha Cognition Inc. | -9.7 Million USD | -1.395% |
| HST Global, Inc. | -5303.00 USD | -185474.203% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -378.415% |
| Halberd Corporation | -74.27 Thousand USD | -13148.697% |
| Enzolytics Inc. | -2.12 Million USD | -363.754% |
| Agentix Corp. | -1.37 Million USD | -617.402% |
| Resverlogix Corp. | -11.74 Million USD | 16.19% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -221.285% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 95.444% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 908.628% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 211.15% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -556.546% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2697.639% |
| AVAX Technologies, Inc. | -6.11 Million USD | -60.994% |
| Zenith Capital Corp. | -8.6 Million USD | -14.35% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.043% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -56389.295% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -302.255% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -5490.703% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -412.309% |
| Kadimastem Ltd | -2.62 Million USD | -274.984% |
| Helix BioMedix, Inc. | -1.04 Million USD | -840.542% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -5334.374% |
| LadRx Corporation | 412.28 Thousand USD | 2486.953% |
| Cell Source, Inc. | -4.27 Million USD | -130.332% |
| Regen BioPharma, Inc. | 1.46 Million USD | 771.303% |
| NovAccess Global Inc. | -1.03 Million USD | -851.008% |
| Affymax, Inc. | -14.29 Million USD | 31.158% |
| Itoco Inc. | -1.86 Million USD | -426.54% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2492.329% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -781.81% |
| Mobile Lads Corp. | -2.24 Million USD | -339.103% |
| CytoDyn Inc. | -18.02 Million USD | 45.416% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -12352.391% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -80372.647% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1926.24% |
| SYBLEU INC | -141.57 Thousand USD | -6851.282% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -826.639% |
| International Stem Cell Corporation | 202 Thousand USD | 4971.782% |
| Bioxytran, Inc. | -3.82 Million USD | -157.608% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -18594.909% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -299.727% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 72.564% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -21768.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -259.423% |
| Neutra Corp. | -181.24 Thousand USD | -5329.607% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 51.183% |
| PureTech Health plc | -11.62 Million USD | 15.361% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 51.18% |
| IXICO plc | -707 Thousand USD | -1291.938% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -28.055% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 79.645% |
| CSL Limited | 4.73 Billion USD | 100.208% |
| Cellectis S.A. | -92.63 Million USD | 89.377% |